Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...

The Department of Health Services has awarded $590 million to Moderna to speed up the development of flu vaccines, including ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Another study found that in late 2021 and 2022, COVID death rates among unvaccinated people were 14 times the rates of those ...

Concerns about the COVID-19 shots have increased after a report that drug maker Moderna failed to inform the U.S. government ...